MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
|
Lymphoma
|
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
|
Lymphoma
|
lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
|
lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria
|
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
loncastuximab tesirine Sensitive: C3 – Early Trials
|
loncastuximab tesirine Sensitive: C3 – Early Trials
|